Shilpa Medicare (NSE:SHILPAMED) Notes Receivable: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SHILPAMED Shilpa Medicare Ltd NSE:SHILPAMED
76 GF Score
Price ₹620.25
GF Value ₹387.78
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Shilpa Medicare Notes Receivable?

Shilpa Medicare NSE:SHILPAMED -2.76% 76 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SHILPAMED with a GF Score™ of 76/100 and a GF Value™ of ₹387.78 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Shilpa Medicare's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Shilpa Medicare Notes Receivable Related Terms

Shilpa Medicare Notes Receivable Historical Data

* Premium members only.

The historical data trend for Shilpa Medicare's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shilpa Medicare Notes Receivable Chart

Shilpa Medicare Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Shilpa Medicare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SHILPAMED
76GF Score
Shilpa Medicare Ltd NSE:SHILPAMED
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shilpa Medicare Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Shilpa Medicare (NSE:SHILPAMED) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Shilpa Medicare and its competitors.
Is Shilpa Medicare's Notes Receivable too high?
Shilpa Medicare's current Notes Receivable is ₹0 Mil. Overall, Shilpa Medicare has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shilpa Medicare's Notes Receivable compare to ZTS and UTHR?
Shilpa Medicare's Notes Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Shilpa Medicare and its competitors. Shilpa Medicare's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shilpa Medicare stock overvalued right now?
Based on GuruFocus' analysis, Shilpa Medicare (NSE:SHILPAMED) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹387.78, compared to a current price of ₹620.25 — trading 59.9% above its estimated fair value. The current Notes Receivable is ₹0 Mil. Shilpa Medicare's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Shilpa Medicare (NSE:SHILPAMED), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shilpa Medicare (NSE:SHILPAMED) Overvalued in 2026?

Based on GuruFocus' analysis, Shilpa Medicare stock appears to be overvalued. The current stock price of ₹620.25 is trading 59.9% above its estimated GF Value™ of ₹387.78. GuruFocus considers Shilpa Medicare to be Significantly Overvalued.

Key valuation signals for NSE:SHILPAMED:

  • Notes Receivable: ₹0 Mil
  • GF Value™: ₹387.78 vs. price of ₹620.25 (59.9% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the NSE:SHILPAMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shilpa Medicare Business Description

Other Exchanges 530549:India
Address Hyderabad Road, No. 12-6-214/A-1, Shilpa House, Raichur, KA, IND, 584135
Shilpa Medicare Ltd is a specialty and generic drug manufacturer. The company deals in high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides, Biotech products, and Specialty Chemicals etc. Its portfolio comprises various oncology and non-oncology-related APIs such as anastrozole, acebrophylline, busulphan, decitabine, etc, and finished dosage formulations such as apremilast tablets, clofarabine injection, docetaxel injection, etc., in various therapy areas. Its reporting segments are: Pharmaceutical product and services, which derive maximum revenue, Power sales, and Others. Geographically, the company generates maximum revenue from India, followed by Europe, the United States of America, and the Rest of the world.
76GF Score

Get the complete analysis for NSE:SHILPAMED

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹620.25
Price
₹387.78
GF Value